Latest Market Sensitivity News

Finexia Financial Group's shares have been suspended from trading pending a significant announcement related to media speculation and a potential material acquisition.

DigiCo Infrastructure REIT confirms its FY25 EBITDA slightly exceeded IPO guidance and aligned with analyst forecasts, attributing recent share price declines to the absence of FY26 earnings guidance.

Pengana International Equities has acknowledged breaching ASX disclosure rules by sharing details of a new private credit strategy with media before official announcement, prompting a policy overhaul.

Kaili Resources Limited has resumed trading on the ASX following a suspension triggered by regulatory queries. The company’s prompt response to ASX concerns has cleared the way for its securities to re-enter the market.

Kaili Resources has officially confirmed a change of control with Mr Jianzhong Yang now holding over 60% of shares, alongside a significant board reshuffle. The company remains focused on advancing its rare earth elements exploration in South Australia.

Challenger Limited reported a 9% increase in normalised net profit after tax for FY25, driven by strong Life business cash earnings and resilient Funds Management performance despite net outflows. The company also announced an 11% dividend increase and provided positive FY26 EPS guidance amid ongoing regulatory reforms.

Kaili Resources has addressed a sharp spike in its share price and trading volume, attributing the market interest to its recent approval for rare earth element drilling in South Australia, while confirming no undisclosed material information.

Nyrada Inc has responded to ASX inquiries confirming the timely and compliant disclosure of positive safety data from its Phase I clinical trial of Xolatryp. The company detailed the timeline of its awareness and release of information, affirming adherence to continuous disclosure rules.

Nutritional Growth Solutions Ltd has voluntarily suspended trading on the ASX pending a capital raising announcement, signaling a pivotal moment for the pediatric nutrition company.

Alterity Therapeutics faces ASX scrutiny after mistakenly marking multiple announcements as market sensitive, prompting a review of its disclosure practices. The biotech denies any intent to manipulate its share price despite repeated errors.

DigitalX Limited has responded to a detailed ASX query regarding its Solana staking yields, exclusive validator agreements, and governance disclosures involving key personnel. The company defends its commercial decisions and compliance amid scrutiny over related party transactions and securities trading.

Battery Age Minerals Ltd has responded to an ASX price query, denying undisclosed information and attributing recent trading activity to a new research report and the launch of its maiden drilling program.